Cardinal Health is increasing its fiscal year 2026 non-GAAP diluted earnings per share to at least $10.00, up from the previous range of $9.65 to $9.85.
The company expects Specialty revenues to exceed $50 billion in fiscal 2026, with a 16% CAGR over three years.
Successful transition of distribution service agreements for pharmaceutical products impacted by the 2026 Medicare Drug Price Negotiation Program.
Introduction of the ContinuCare™ Pathway program to simplify diabetes supply management and partnership with Publix Super Markets Inc.
Raised Outlook
Fiscal year 2026 non-GAAP diluted EPS increased to at least $10.00.
Specialty Growth
Anticipates over $50 billion in Specialty revenues with a 16% CAGR.
IRA Changes
Successfully transitioned distribution service agreements for pharmaceutical products affected by the 2026 Medicare Drug Price Negotiation Program.
ContinuCare™ Pathway
Introduced a program to simplify diabetes supply management and partnered with Publix Super Markets Inc.
- Cardinal Health demonstrates strong performance and execution leading to the outlook raise.
- Specialty revenue growth is attributed to demand across distribution sectors and new platforms like BioPharma Solutions.
- Successful transition post-IRA changes reflects Cardinal Health's value proposition and essential healthcare role.
- ContinuCare™ Pathway program enhances customer service, simplifies processes, and expands patient access.
The strategic updates and favorable outlook adjustments position Cardinal Health as a key player in the healthcare sector, showcasing innovation and growth prospects.